MitonafideAlternative Names: M 4212; NSC 300288
Latest Information Update: 05 Feb 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer